Azar to doctors: HHS is listening to feedback on its Medicare reforms aimed at drug prices

Alex Azar
The HHS Secretary says the agency is listening to doctors as it marches toward lower drug prices. (CSPAN)

The Department of Health and Human Services won’t be able to bring down prices in Part D without “pitting drugs against each other,” Secretary Alex Azar said Tuesday.

The HHS head said that the agency is aware step therapy and other similar approaches can require a greater need for prior authorization or can create confusion about which drugs are available—but having these tools at a plan's disposal is crucial. 

“Any talk about lower drug prices in Part D without a way to pit drug options against each other is really just hot air and empty promises,” Azar said at the American Medical Association’s National Advocacy Conference. 


9 Tips for Implementing the Best Mobile App Strategy

The member mobile app is a powerful tool for payers and members. It can help improve health outcomes, reduce operational costs, and drive self-service — anytime, anywhere. In this new eBook, learn tips and tricks to implementing the best mobile app strategy now.

Part D plans have traditionally used step therapy as an option to manage costly conditions like diabetes and or high cholesterol—and the Centers for Medicare & Medicaid Services has proposed extending the option to Medicare Advantage plans to use in Part B

Provider groups—including the AMA—have pushed back on that idea. 

RELATED: Payers, providers clash on CMS’ plans for step therapy in Medicare Part B 

Though Azar’s speech focused on changes in Part D, he said HHS is listening closely to what physicians and groups like AMA have to say about the pieces of their drug pricing blueprint. He noted that AMA’s comments in response to the agency’s accompanying request for information said doctors are frequently unaware of what medications are on the formulary for a patient’s plan. 

To ease some of the burden associated with step therapy, he said HHS has proposed a requirement that Part D plans use a pharmacy benefit tool that would make more information about coverage immediately accessible electronically. 

In addition, CMS proposed in a rule earlier this week enforcing the use of tools that would allow data to better follow patients between plans, as they may have to start a step therapy regimen over if they enroll in a new health plan. 

HHS wants to hear from doctors on how to address this concern, he said. 

“This is not just potentially injurious to [a patient’s] health—it's also pennywise and pound foolish,” Azar said. “We know that getting a patient on the right drug, at the right time, is one of the best investments we can make in their health.” 

Azar stumps for agency’s International Pricing Index 

In addition to focusing on HHS’ plans for Part D, Azar also took time in the speech to promote its International Pricing Index model, which would peg the prices of Part B drugs to those paid in other countries

RELATED: The ‘vendors’ in HHS’ new drug pricing plan sound an awful lot like PBMs, experts say 

One of the plans’ more curious features is the role that drug vendors would play. Azar said that the goal is to provide options to providers who may not be able to spend significant amounts of upfront money to keep certain Part B products in stock. 

An individual physician practice, for example, would have the option to hire a vendor to do their negotiations, and that vendor would own the drugs themselves. However, if a larger physician group has the leverage to do their own negotiating, that’s also an option, he said. 

While the model’s central goal is to eliminate a “corporate welfare system” that benefits drug manufacturers, physicians were also considered in the model’s design. 

“We believe that the lower costs will, of course, mean better patient access to drugs, better adherence and better outcomes for the care you provide—that is the goal,” Azar said.

Suggested Articles

Here's who is on board to take Wayne Smith's place as CEO of Community Health Systems.

COVID-19 has dramatically accelerated the adoption of digital health, and a new analysis from Deloitte finds that trend extends similarly to MA.

Centene Corporation earned $568 million in profit in the third quarter, a huge boost compared to its third-quarter 2019 earnings of $95 million.